UroGen Pharma (URGN) Tops Q2 EPS by 8c, beats revenue, reiterates guidance

UroGen Pharma (NASDAQ: URGN) reported Q2 EPS of ($1.03), $0.08 better than the analyst estimate of ($1.11). Revenue for the quarter came in at $21.14 million versus the consensus estimate of $20.12 million.

2023 Revenue, Operating Expense and RTW Expense Guidance:

The Company reiterates anticipated full year 2023 net product revenues from JELMYTO to be in the range of $76 to $86 million. The Company also reiterates anticipated full year 2023 operating expenses in the range of $135 to $145 million, including non-cash share-based compensation expense of $6.0 to $11.0 million, subject to market conditions. The Company also reiterates anticipated full year 2023 non-cash financing expense related to the prepaid obligation to RTW Investments in the range of $21.0 to $26.0 million. Of this amount approximately $9.9 to $11.2 million is expected to be in cash.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Ideal Power (IPWR) Tops Q2 EPS by 2c
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation